Wedbush Research Analysts Lower Earnings Estimates for OVID

Ovid Therapeutics (NASDAQ:OVID) – Stock analysts at Wedbush lowered their Q3 2025 earnings per share (EPS) estimates for Ovid Therapeutics in a report released on Wednesday, August 13th. Wedbush analyst L. Chico now expects that the company will earn ($0.15) per share for the quarter, down from their previous estimate of ($0.14). The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics’ FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.53) EPS.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Wednesday, August 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.10. Ovid Therapeutics had a negative return on equity of 58.87% and a negative net margin of 574.44%. The firm had revenue of $6.27 million for the quarter, compared to analyst estimates of $0.09 million.

A number of other equities research analysts have also commented on the company. William Blair raised Ovid Therapeutics to a “strong-buy” rating in a research report on Thursday, April 24th. Wall Street Zen raised Ovid Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. B. Riley reaffirmed a “buy” rating and set a $3.00 price target on shares of Ovid Therapeutics in a research report on Friday, August 8th. Finally, HC Wainwright dropped their price target on Ovid Therapeutics from $2.00 to $1.50 and set a “buy” rating on the stock in a research report on Tuesday, May 27th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $3.10.

Ovid Therapeutics Trading Up 15.4%

NASDAQ:OVID opened at $0.97 on Monday. The firm has a market capitalization of $68.98 million, a price-to-earnings ratio of -1.83 and a beta of 0.20. The company has a current ratio of 4.72, a quick ratio of 4.72 and a debt-to-equity ratio of 0.23. The business’s 50-day moving average price is $0.45 and its two-hundred day moving average price is $0.42. Ovid Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.47.

Institutional Trading of Ovid Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its position in shares of Ovid Therapeutics by 49.7% during the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after purchasing an additional 18,841 shares during the last quarter. Velan Capital Investment Management LP acquired a new stake in shares of Ovid Therapeutics in the 4th quarter valued at approximately $65,000. XTX Topco Ltd acquired a new stake in shares of Ovid Therapeutics in the 1st quarter valued at approximately $29,000. Renaissance Technologies LLC boosted its holdings in shares of Ovid Therapeutics by 142.0% in the 4th quarter. Renaissance Technologies LLC now owns 107,700 shares of the company’s stock valued at $101,000 after buying an additional 63,200 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Ovid Therapeutics in the 1st quarter valued at approximately $37,000. Institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.